Cantor Fitzgerald Maintains Overweight on NewAmsterdam Pharma Co, Raises Price Target to $61

Benzinga · 2d ago
Cantor Fitzgerald analyst Steve Seedhouse maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight and raises the price target from $52 to $61.